Evidence map›Paper›PMID 37129249›Full record

ArticlePsychological medicine2023

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.

Edoardo Spinazzola, Diego Quattrone, Victoria Rodriguez, Giulia Trotta, Luis Alameda, Giada Tripoli, Charlotte Gayer-Anderson, Tom P Freeman, Emma C Johnson, Hannah E Jongsma and 36 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychological medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 8 countries.

Edoardo SpinazzolaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.ORCID 0000-0002-8070-0618
Diego QuattroneSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.ORCID 0000-0002-6051-8309
Victoria RodriguezDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Giulia TrottaSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.ORCID 0000-0003-2801-9718
Luis AlamedaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.ORCID 0000-0002-8621-2885
Giada TripoliDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.ORCID 0000-0002-9257-6677
Charlotte Gayer-AndersonDepartment of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0003-1636-889X
Tom P FreemanAddiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Emma C JohnsonDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Hannah E JongsmaPsylife Group, Division of Psychiatry, University College London, London, UK.
Simona StiloDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Caterina La CasciaBiomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
Laura FerraroBiomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
Daniele La BarberaBiomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
Antonio LasalviaSection of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Sarah TosatoSection of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Ilaria TarriconeDepartment of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
Giuseppe D'AndreaDepartment of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
Michela GalatoloDepartment of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
Andrea TortelliInstitut Mondor de recherché biomedicale, Creteil, France.
Ilaria TagliabueDepartment of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Marco TurcoDepartment of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Maurizio PompiliDepartment of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Jean-Paul SeltenRivierduinen Institute for Mental Health Care, Leiden, The Netherlands.
Lieuwe de HaanEarly Psychosis Section, AmsterdamUMC, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands.
Paulo Rossi MenezesDepartment of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.
Cristina M Del BenDepartment of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.
Jose Luis SantosDepartment of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.
Manuel ArrojoDepartment of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.
Julio BobesDepartment of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.
Julio SanjuánDepartment of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Valencia, Spain.
Miguel BernardoBarcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Biomedical Research Networking Centre in Mental Health (CIBERSAM), Barcelona, Spain.
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
James B KirkbrideReader; Psylife Group, Division of Psychiatry, University College London, London, UK.
Peter B JonesDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Michael O'DonovanDivision of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
Bart P RuttenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
Jim Van OsDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Craig MorganDepartment of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Pak C ShamDepartment of Psychiatry, Centre for PanorOmic Sciences, and State Key Laboratory of Brain and Cognitive Sciences, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Isabelle Austin-ZimmermanSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Zhikun LiSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Evangelos VassosSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
EU-GEI WP2 Group
Robin M MurrayDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
Marta Di FortiSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.ORCID 0000-0002-3218-6925
King's College London · GBUniversity of Bologna · ITUniversity of Palermo · ITMaastricht University Medical Centre · NLUniversidade de São Paulo · BRUniversity of Verona · ITAmsterdam University Medical Centers · NLAziende Socio Sanitarie Territoriali di LeccoCardiff University · GBCentro de Investigación Biomédica en Red de Salud Mental · ESChinese University of Hong Kong · HKComplejo Hospitalario Universitario de Santiago · ESHospital General Universitario Gregorio Marañón · ESHospital Virgen de la Luz · ESInstitut Mondor de Recherche Biomédicale · FRSapienza University of Rome · ITThe London College · GBUniversidad de Oviedo · ESUniversitat de València · ESUniversity College London · GB

Funding

Identifying genetic sources of comorbidity between cannabis and schizophrenia using genome-wide and integrative omics dataK01DA051759 · NIDA · WASHINGTON UNIVERSITY · PI JOHNSON, EMMA COVEY · 2021 to 2025
$816k
Medical Research Council MR/L010305/1Medical Research Council MR/W030608/1NIDA NIH HHS K01 DA051759NIDA NIH HHS K01DA051759Wellcome TrustWellcome Trust 101272/Z/12/Z
6 · The paper itself

Abstract

backgroundWhile cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis.

methodsWe used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status.

resultsControls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: 'to feel better' as their RFUC (χ

conclusionsBoth FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.

Indexed as

CannabisMarijuana SmokingPsychotic DisordersCase-Control StudiesHumansRisk FactorsCannabis usepath analysispsychotic disorders

Identifiers

PMID37129249
PMCPMC10719678
OpenAlexW4367669246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.